Protalix BioTherapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $14.7M | $19.8M | $23.6M | $17.1M | $39.0M | $18.3M | $17.8M | $37.8M |
| Accounts Receivable | $8.8M | $2.9M | $5.3M | $4.6M | $3.4M | $2.0M | $4.7M | $4.7M |
| Inventory | $25.7M | $21.2M | $19.0M | $16.8M | $18.0M | $13.1M | $8.2M | $8.6M |
| Total Current Assets | $66.7M | $60.1M | $69.9M | $44.9M | $61.7M | $55.7M | $32.5M | $53.0M |
| Property, Plant & Equipment | $4.9M | $4.6M | $5.0M | $4.6M | $5.0M | $4.8M | $5.3M | $6.4M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $82.3M | $73.4M | $84.4M | $55.8M | $73.7M | $67.9M | $45.4M | $61.1M |
| Liabilities | ||||||||
| Accounts Payable | $5.3M | $4.5M | $19.6M | $12.3M | $16.4M | $13.9M | $11.9M | $10.3M |
| Total Current Liabilities | $26.5M | $25.6M | $45.5M | $32.4M | $33.2M | $86.5M | $40.2M | $25.4M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $34.1M | $30.2M | $50.9M | $66.4M | $79.7M | $95.0M | $115.7M | $114.0M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-385.0M | $-378.4M | $-381.5M | $-389.9M | $-374.9M | $-347.4M | $-340.8M | $-322.6M |
| Total Stockholders' Equity | $48.2M | $43.2M | $33.6M | $-10.6M | $-6.0M | $-27.0M | $-70.3M | $-52.9M |